Province moves to protect supply of two more diabetes drugs

British Columbia limits sales of tirzepatide and dulaglutide to ensure that people with diabetes have reliable access to these essential medications amid ongoing shortages. The provincial government enacted a regulation in April 2023, initially targeting semaglutide, to curb off-label sales for weight loss. Health Minister Josie Osborne highlighted that the off-label use of diabetes medications is impacting supply chains in multiple countries. Under the new regulation, only B. C.

residents, Canadian citizens, and permanent residents can purchase these drugs from pharmacies. Non-Canadian residents may still obtain medications in person if they have a valid prescription from a Canadian healthcare provider. The College of Pharmacists of B. C. has been tasked with enforcing compliance with this regulation.

This move reflects the government's commitment to prioritizing public health and ensuring that those with diabetes can access necessary treatments. With rising demand for these medications, the government’s actions aim to stabilize the supply for the most vulnerable populations.